File size: 2,666 Bytes
ace6b64 eb9f3cc bc8ae3b eb9f3cc |
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 |
import nltk
nltk.download(['stopwords', 'punkt'])
from summarize import summarize
from data import data
import streamlit as st
st.write("""
# Pharma Company POC
""")
st.sidebar.image("./NarrativaLogoBlanco.png")
def make_summarizing(new_body, hide=False, num_sentences=3):
if hide:
return ''
result = summarize(
new_body, sentence_count=num_sentences, language='english')
return result
st.subheader("Overview")
st.write("""
##### Topics:
- Cancer
- immuno-oncology
- New Therapy
- BiTE
""")
st.write("""
##### Summary:
""")
st.write(make_summarizing(data["intro"]))
st.write('---')
st.write('##### Conversation:')
st.write("""
***Overview of the current therapeutic landscape for cancer and the immuno-oncology***
""")
st.write(make_summarizing(data["block_1"]))
st.write("""
***How does the BiTE platform and constituent BiTE molecules actually work***
""")
st.write(make_summarizing(data["block_2"], num_sentences=4))
st.write("""
***Where BiTE molecules are currently being studied***
""")
st.write(make_summarizing(data["block_3"], num_sentences=3))
st.write("""
***Practial approach: Myeloma and BiTE***
""")
st.write(make_summarizing(data["block_4"], num_sentences=6))
st.write("""
***Acute Myeloid Leukemia and BiTE molecules***
""")
st.write(make_summarizing(data["block_5"], num_sentences=6))
st.write("""
***BiTE molecules for solid tumor types***
""")
st.write(make_summarizing(data["block_6"], num_sentences=4))
st.write("""
***Takeaways***
""")
st.write(make_summarizing(data["block_7"], num_sentences=3))
st.write("""
# MRD Slide Deck
""")
st.write("""
### Current Landscape in Minimal Residual Disease (MRD) Testing in Hematologic Malignancies
""")
st.write("""
- MRD is the presence of malignant cells under the detection limit of conventional methods
- Strong prognostic indicator of patient outcomes
- Potential for use in guiding treatment decisions
- Intensity of therapy
- Appropriateness of SCT
- Currently measured using flow cytometry or qPCR
- Newer testing methods are emerging
- MRD is currently being evaluated as a potential surrogate endpoint, and may have the potential to replace or augment morphological CR as a response criteria in certain hematologic malignancies
""")
|